Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-18-096773
Filing Date
2018-03-27
Accepted
2018-03-27 08:41:32
Documents
6
Period of Report
2018-03-27

Document Format Files

Seq Description Document Type Size
1 6-K d558285d6k.htm 6-K 17792
2 EX-99.1 d558285dex991.htm EX-99.1 152602
3 EX-99.2 d558285dex992.htm EX-99.2 27455
4 EX-99.3 d558285dex993.htm EX-99.3 12655
5 GRAPHIC g558285g0327162903877.jpg GRAPHIC 3160
6 GRAPHIC g558285img001.jpg GRAPHIC 10772
  Complete submission text file 0001193125-18-096773.txt   231122
Mailing Address 136A EASTERN AVENUE MILTON PARK ABINGDON X0 OX14 4SB
Business Address 136A EASTERN AVENUE MILTON PARK ABINGDON X0 OX14 4SB 44-123-544-3939
Summit Therapeutics plc (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0114
Type: 6-K | Act: 34 | File No.: 001-36866 | Film No.: 18714163
SIC: 2834 Pharmaceutical Preparations